Anth1 chimeric antagonist

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 15/62 (2006.01) A61K 31/7088 (2006.01) A61K 38/20 (2006.01) A61K 38/21 (2006.01) A61K 48/00 (2006.01) A61P 29/00 (2006.01) C07K 14/55 (2006.01) C07K 14/715 (2006.01) C07K 19/00 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2485439

The invention relates to a recombinant chimeric protein comprising a fragment of 60 amino acids from the N-terminal region of the human interleukin 2 (IL-2) fused to the N-terminal of the extracellular region of the alpha chain of the receptor for IFN gamma (IFN .gamma.). Said in vitro protein exhibits T cell growth-stimulating activity, inhibits IL-2 growth-stimulating activity in T cells, inhibits the induction of HLA-DR by IFN .gamma. and inhibits the antiproliferative activity of IFN .gamma.. The invention is suitable for use in medicine for the treatment of various pathologies, such as autoimmune diseases, transplantation rejections, chronic inflammations, sepsis, ischemia and reperfusion syndrome and atherosclerosis.

L'invention concerne une protéine chimérique recombinante composée d'un fragment de 60 acides aminés du domaine N-terminal de l'interleukine 2 (IL-2) humaine fusionné au domaine N-terminal de la région extracellulaire de la chaîne alpha du récepteur de IFN gamma (IFN .gamma.). Cette protéine in vitro présente une activité qui stimule la croissance des lymphocytes T, inhibe l'activité de stimulation de la croissance de IL-2 dans des lymphocytes T, inhibe l'induction de HLA-DR par IFN .gamma. et inhibe l'activité antiproliférative de IFN .gamma.. L'invention peut être appliquée en médecine afin de traiter différentes maladies, telles que les maladies auto-immunes, les rejets de transplantations, les inflammations chroniques, les septicémies, le syndrome d'ischémie-reperfusion et l'athérosclérose.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Anth1 chimeric antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anth1 chimeric antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anth1 chimeric antagonist will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1995823

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.